Combretastatin A4

Catalog No.S7783

Combretastatin A4 Chemical Structure

Molecular Weight(MW): 316.35

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.

Size Price Stock Quantity  
USD 97 In stock
USD 397 In stock
USD 997 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.
Targets
β-tubulin [1]
0.4 μM(Kd)
In vitro

Combretastatin A4 inhibits the growth of MDA-MB-231, A549, Hela, HL-60, SF295, HCT-8, MDA-MB435, PC3M, OVCAR-8, NCI-H358M, and lymphocyte cells with IC50 of 2.8, 3.8, 0.9, 2.1, 6.2, 5.3, 7.9, 4.7, 0.37, 8, and 3.2 nM, respectively.[1] [2] 1 μM Combretastatin A4 inhibits tubulin polymerization by 35%, and 10 μM nearly completely blocks tubulin polymerization. Combretastatin A4 demonstrates great relative binding capacity, reaching 78% of colchicine binding.[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SKMEL-5 M{npeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFPHT5dEgXSxdH;4bYMh[2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JFUxLSClZXzsJIdzd3e2aDDpckBUU02HTD21JI1mdGGwb33hJINmdGxibHnu[ZMtKEWGNUC9N{4xOEVvMEig{txO NUf0fJVUOTh5NUO1NC=>
A-549 Mlm4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUD5NotbS3m2b4TvfIlkKGOxbnPlcpRz[XSrb36gdoVyfWm{ZXSgeI8hcW6qaXLpeEA2OCViY3XscEBoem:5dHigbY4hSS13NEmgcJVv\yClYYLjbY5wdWFiY3XscEBtcW6nczygSWQ2OD1zLkKwSU0xPiEQvF2= NXW5Z2tQOTh5NUO1NC=>
MCF-7 NGS2ZmhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MonpR5l1d3SxeHnjJINwdmOnboTyZZRqd25icnXxeYlz\WRidH:gbY5pcWKrdDC1NEUh[2WubDDndo94fGhiaX6gUWNHNTdiYoLlZZN1KGOjcnPpco9u[SClZXzsJIxqdmW|LDDFSFUxRTNwOEDFMVA3KM7:TR?= MVuxPFc2OzVy
HT-29 NV7ER2N3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIf1THdEgXSxdH;4bYMh[2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JFUxLSClZXzsJIdzd3e2aDDpckBJXC1{OTDjc4xwdiCjZHXuc4NiemOrbn;tZUBk\WyuIHzpcoV{NCCHREWwQVEvOjCHLUC2JO69VQ>? NXzhZ2JVOTh5NUO1NC=>
MLM melanoma cell NFH0[nZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3W0UWN6fG:2b4jpZ{Bkd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgOVAmKGOnbHyg[5Jwf3SqIHnuJG1NVSCvZXzhco9u[SClZXzsJIxqdmW|LDDFSFUxRTFwNEDFMVA3KM7:TR?= NV;CWm5iOTh5NUO1NC=>
M14 Ml;UR5l1d3SxeHnjbZR6KGG|c3H5 MVTJckB3cXS{bzDjfZRwfG:6aXOgZYN1cX[rdImge4F{KHSnc4Tl[EBi\2GrboP0JIh2dWGwIH3lcIFvd22jIHPhcoNmeiBqTUG0LUBk\WyuIHzpcoUtKEeLNUC9NE4xODBzIN88US=> NYLFZWx2OTJ5Mkm2OFA>
SK-OV3 MV7DfZRwfG:6aXPpeJkh[XO|YYm= NYPWSplCUW5idnn0do8h[3m2b4TvfIlkKGGldHn2bZR6KHSnc4Tl[EBi\2GrboP0JIh2dWGwIH;2ZZJq[W5iY3HuZ4VzKCiVSz3PWlMqKGOnbHygcIlv\SxiR1m1NF0xNjByMEGg{txO M2PNZVEzPzJ7NkSw
HL60 cells Mn7zR5l1d3SxeHnjbZR6KGG|c3H5 NVOzT|JXPzJiaB?= M2\5OmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhNPjBiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlAxODFizszN M1LMVlIxPzNzM{W1
SK-OV-3 MmXQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MU[0PEBp NV7hb4RyT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvT2[tN{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAxOTNizszN M33kS|E5PzJ{MUK3
HepG2 cells MYrDfZRwfG:6aXPpeJkh[XO|YYm= NXHpdotMS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNuIFnDOVA:OC5yMECxOEDPxE1? NIHXbmkyPzF{N{C2NS=>
ZR-75-1 Mn24R5l1d3SxeHnjbZR6KGG|c3H5 MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBbWi15NT2xJINmdGxibHnu[UwhUUN3ME2wMlAxODJ2IN88US=> NFHqSnUyPzJ2OU[0PS=>
HeLa cell MYjDfZRwfG:6aXPpeJkh[XO|YYm= MmrhR5l1d3SxeHnjbZR6KGGpYXnud5QhUGWOYTDj[YxtKGyrbnWsJGlEPTB;MD6wNFA{KM7:TR?= NH7sWW8yPzJ2OU[0PS=>
HCT116 cell MmnuR5l1d3SxeHnjbZR6KGG|c3H5 NV\U[otpS3m2b4TvfIlkcXS7IHHnZYlve3RiSFPUNVE3KGOnbHygcIlv\SxiSVO1NF0xNjByMEO1JO69VQ>? NXnSdWhZOTd{NEm2OFk>
KBV1 cells MonlR5l1d3SxeHnjbZR6KGG|c3H5 NVTRN3ZnPzJiaB?= M3zKfGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJJZqdmKuYYP0bY5mNXKnc3nzeIFvfCCNQm[xJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEC0JO69VQ>? MXOyNFc{OTN3NR?=
SKOV3 MYTDfZRwfG:6aXPpeJkh[XO|YYm= MUfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT29XOyClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEC0NkDPxE1? M1vsSlI1ODF4MECy
SKOV3 cells NYHJcYp{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnjRS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV2tQXjNiY3XscJMh[nlic4Xs[o9zcG:mYX3pcoUhSiCjc4PhfUwhT0l3ME2wMlAxODR{IN88US=> NW\4[3dvOjN5N{KzNFk>
HeLa cells MlfRR5l1d3SxeHnjbZR6KGG|c3H5 NY\PUpZwS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFA2OSEQvF2= NVOzeWx4OTl6N{m3OVg>
DU145 cells Mlz1R5l1d3SxeHnjbZR6KGG|c3H5 MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:OC5yMEC1OEDPxE1? MXGyOFAyPjByMh?=
DU145 cells NH\tbXFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnL6S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gSHUyPDViY3XscJMh[nlic4Xs[o9zcG:mYX3pcoUhSiCjc4PhfUwhT0l3ME2wMlAxODV2IN88US=> NYftOGxZOjN5N{KzNFk>
SK-N-BE MWLQdo9tcW[ncnH0bY9vKGG|c3H5 M{LYO|czKGh? NVPwVlUzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkhcW5iaIXtZY4hW0tvTj3CSUBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECwOVgh|ryP M1ywOlIzOzJ7NU[x
NCIH460 cells NH:5c5lEgXSxdH;4bYNqfHliYYPzZZk> NIHjN5Y1QCCq M3nyc2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUUh2NkCgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjByME[g{txO NXfNSpBnOTh|MEO4OFk>
KB-VIN10 cells MVrQdo9tcW[ncnH0bY9vKGG|c3H5 MkDlO|IhcA>? NIrlbmFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvCMXZKVjFyIHPlcIx{KG:4ZYKt[ZhxemW|c3nu[{BRNWeyIEG3NE9OTFJzIHHmeIVzKDd{IHjyd{BjgSCvZYTofYxmdmViYnz1[UBie3OjeTygTWM2OD1yLkCwNFch|ryP NFzDR|MzOTZ2MUewNC=>
HCT116 cells NVPKfZJKS3m2b4TvfIlkcXS7IHHzd4F6 M37sT|czKGh? M1u1c2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YhYzOKXYTofY1q\GmwZTDpcoNwenCxcnH0bY9vKGGodHXyJFczKGi{czDifUB{[2mwdHnscIF1cW:wIHPveY51cW6pLDDJR|UxRTBwMECwO|Qh|ryP MUmyNVk2PTR3NB?=
DU145 cells MULDfZRwfG:6aXPpeJkh[XO|YYm= Mn[3OFghcA>? NYfyeI9YS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjByMEig{txO MXmxPFMxOzh2OR?=
RS4:11 cells NW\yXGlRWHKxbHnm[ZJifGmxbjDhd5NigQ>? MVG3NkBp NF2wdnpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGLTOFoyOSClZXzsd{Bi\nSncjC3NkBpenNiYomgLFMuMDRuNT3kbY1mfGi7bITobYF7d2xvMj35cEkuOix3LXTpdIhmdnmudHX0doF7d2yrdX2gZpJwdWmmZTD0[ZN1NCCLQ{WwQVAvODByODFOwG0> MlHENlU4QDV4MEW=
HCT 116 NVTF[XVKT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXHDc45k\W62cnH0bY9vKHeqaXPoJJBzd2S3Y3XzJFUxLSCrbnjpZol1cW:wIH;mJIdzd3e2aDDv[kBpfW2jbjDjc4xwdiC2dX3vdkBJS1RiMUG2MEBKSzVyPUCuNFAxQSEQvF2= MXqxNVcyPDZzMx?=
HeLa cells MYfDfZRwfG:6aXPpeJkh[XO|YYm= MlnSO|IhcA>? NUfGdIVFS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCjZoTldkA4OiCqcoOgZpkhemW|YYr1dolvKGKjc3XkJIZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3ME2wMlAxODlizszN M4DSNVI1PjZ7OEi4
BNL 1ME A.7R.1 cells NUjWXIZTS3m2b4TvfIlkcXS7IHHzd4F6 MnroR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRm5NKDGPRTDBMldTNjFiY3XscJMtKEmFNUC9NE4xODB7IN88US=> NF23PWkzPTd6NU[wOS=>
Calu6 NXPkc3JRWHKxbHnm[ZJifGmxbjDhd5NigQ>? M3m5VFQ5KGh? NEPEUHNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPhcJU3KGGodHXyJFQ5KGi{czDifUB{eGWldILvdIhwfG:vZYTyfUwhUUN3ME2wMlAxODl2IN88US=> MW[yNVc4PDR7OR?=
melanoma B16 cell NV;xRW9ST3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUfqdmxoS2:wY3XueJJifGmxbjD3bIlkcCCycn;keYNmeyB3MDWgbY5pcWKrdHnvckBw\iCpcn;3eIghd2ZibYXybY5mKG2nbHHuc41iKEJzNjDj[YxtKGyrbnWsJGlEPTB;MD6wNFEh|ryP MoDUNVE4OTR4MUO=
DU145 cells MWXDfZRwfG:6aXPpeJkh[XO|YYm= MnTZR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSHUyPDViY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECxJO69VQ>? MWKyNFQ6Pjl{Mx?=
HCT116 cells NU\nT45tWHKxbHnm[ZJifGmxbjDhd5NigQ>? MUS3NkBp NEjpbZJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRUKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= MlzYNlEyOTJzM{C=
HCT15 cells NHPUWZVRem:uaX\ldoF1cW:wIHHzd4F6 NW\HXXJMPzJiaB?= MYfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEG1JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVA:OC5yMEGg{txO NX:5OGZ7OjFzMUKxN|A>
HL60 cells Ml7XVJJwdGmoZYLheIlwdiCjc4PhfS=> NVr3UoFpPzJiaB?= NILINHlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMOlAh[2WubIOgZZN{\XO|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlAxOSEQvF2= NWHocGUyOjF4NkOzNVk>
A10 cells MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoPIOFghcA>? NXHDWoFMT3Kxd4ToJIlvcGmkaYTpc44hd2ZicnH0JGEyOCClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= M1ywdlIzODR2MU[0
HUVEC cells MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHnhZW01QCCq NXi3S5d3T3Kxd4ToJIlvcGmkaYTpc44hd2ZiSGXWSWMh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? MYOyNlA1PDF4NB?=
HL60 cells M1eyRWN6fG:2b4jpZ4l1gSCjc4PhfS=> Mnj2O|IhcA>? Mnf5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGw3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= MYSyNlE{PjNzMh?=
HL60 cells NH;HfJhRem:uaX\ldoF1cW:wIHHzd4F6 MlTVO|IhcA>? NELp[VdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMOlAh[2WubIOgZZN{\XO|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlAxOSEQvF2= Mmf4NlI2PzhzMUG=
NCI-H522 cells MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIfSVXM1QCCq MX\Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kuUDV{MjDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwQVAvODBzIN88US=> MXeyNlk5OjF{Mh?=
MDA-MB-435 cells M{jmSmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVjxcYhNPDhiaB?= M3[5eWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj20N|Uh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNUDPxE1? NI\yTG8zOjl6MkGyNi=>
OVCAR3 Mmj2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIfPdWI1QCCq MWrHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDPWmNCWjNiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlAxOSEQvF2= MmLENlI6QDJzMkK=
NCI/ADR-RES cells NXjwTYVNT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Ml7vOFghcA>? MWrHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kwSUSULWLFV{Bk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECxJO69VQ>? MoHiNlI6QDJzMkK=
PC3 cells NXH1ZmdlT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEHoS401QCCq M4jw[Gdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHBEOyClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAyKM7:TR?= NVLxe2JOOjJ7OEKxNlI>
DU145 cells MmHoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{HHSVQ5KGh? MmfrS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gSHUyPDViY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlAxOSEQvF2= MlPPNlI6QDJzMkK=
MDA-MB-231 cells MnPDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlHZOFghcA>? Mmn4S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECxJO69VQ>? M4HQb|IzQTh{MUKy
CEM cells NFyxWHREgXSxdH;4bYNqfHliYYPzZZk> MXq3NkBp Mn3jR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2VOKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP M2XRZlIzPjd4MkS3
HCT116 cells Mn\pR5l1d3SxeHnjbZR6KGG|c3H5 M2faWlczKGh? NES4S4tEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByMTFOwG0> NUiydmpCOjJ4N{[yOFc>
MDA-MB-435 cells Mn7WR5l1d3SxeHnjbZR6KGG|c3H5 NIDpOnY4OiCq MYPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNEO1JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO NEXnXlMzOjZ5NkK0Oy=>
HaCaT cells NU\4[Xp3WHKxbHnm[ZJifGmxbjDhd5NigQ>? Mm\aRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKYVPhWEBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDifUBOXFRiYYPzZZktKEmFNUC9NE4xODFizszN MmS0NlMxPjN2MEG=
HL60 cells NYXGdGxqWHKxbHnm[ZJifGmxbjDhd5NigQ>? MmDGO|IhcA>? MUPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByMTFOwG0> Mo\mNlMyOTdzN{G=
HL60 cells NEm2UGxRem:uaX\ldoF1cW:wIHHzd4F6 MWG3NkBp MX3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KCh|LTi0MFUu\GmvZYTofYx1cGmjen;sMVIugWxrLUKsOU1lcXCqZX75cJRmfHKjen;sbZVuKGK{b33p[IUhfGW|dDygTWM2OD1yLkCwNUDPxE1? NU\kdXFuOjV5OEW2NFU>
HT-29 NUDieWI3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlT4S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTHQuOjliY3XscJMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? NWfzfm1zOjV4OEmxNVE>
HL60 cells MmfqVJJwdGmoZYLheIlwdiCjc4PhfS=> MkXiO|IhcA>? M1O4WWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? MWiyNFQzODR|OR?=
Hs578T cells NGO4W25Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEfSem01QCCq M3jZUWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGh{PTd6VDDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwQVAvODBzIN88US=> NEnqWnozOjl6MkGyNi=>
HL60 cells MXPDfZRwfG:6aXPpeJkh[XO|YYm= Mm\2O|IhcA>? MVfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP NHK4PW0zOzR2NUS5Oi=>
SKOV3 cells NGnKdoRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXn2VodpT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW0uRVkOgZ4VtdHNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= NVPBc3B5OjV4OEmxNVE>
MDA-MB-468 cells Mm[5R5l1d3SxeHnjbZR6KGG|c3H5 MX[0JIRigXN? NXvSV|RoS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ3QCClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC0JIRigXNiYomgUXRUKGG|c3H5MEBKSzVyPUCuNFAyOSEQvF2= MUCyOFIyODVyMx?=
MCF7 cells NUCxWHFjWHKxbHnm[ZJifGmxbjDhd5NigQ>? NEK5epo4OiCq MWLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDpckBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEyOSEQvF2= MVGyNlMzQTV4MR?=
H460 NXnJenhLS3m2b4TvfIlkcXS7IHHzd4F6 NHuzTVZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJPDZyIHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJidHXzeEwhUUN3ME2wMlAxOTJizszN MVexPFc5OzJyNx?=
H460 NH7MdIVRem:uaX\ldoF1cW:wIHHzd4F6 M2jwT2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSES2NEBk\WyuczygTWM2OD1yLkCwNVI1KM7:TR?= NFrsb2cyPjd{Mk[zNy=>
NCI-H460 cells MlPzR5l1d3SxeHnjbZR6KGG|c3H5 NEDxfVM4OiCq NHHD[ZBEgXSxdH;4bYMh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDR4MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkB1\XO2LDDJR|UxRTBwMECxN{DPxE1? NX3Pe4VROTh|OU[4OVc>
OVCAR8 cells MmK4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1PtR|k3KGh? M2D3R2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GUODDj[YxteyCxdnXy[ZhxemW|c3nu[{BRNWeueXPvdJJwfGWrbjDh[pRmeiB7NjDodpMtKEmFNUC9NE4xODF|IN88US=> M2G1flIzODR2MU[0
NCI/ADR-RES cells MnnDR5l1d3SxeHnjbZR6KGG|c3H5 NH3nd|lEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lxQVTSMXJGWyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCkeTD0dplx[W5iYnz1[UBmgGOudYPpc44h[XO|YYmsJGlEPTB;MD6wNFE{KM7:TR?= M1;pNlI{OjF2NEWy
OVCAR8 cells Mon4R5l1d3SxeHnjbZR6KGG|c3H5 M3XTZVk3KGh? MUjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDPWmNCWjhiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhQTZiaILzJIJ6KEerZX3zZUB{fGGrbnnu[{1j[XOnZDDsbYdpfCCvaXPyc5Nkd3C7LDDJR|UxRTBwMECxN{DPxE1? M2XxRVI2ODJ3OUmx
NCI/ADR-RES cells NHjpbFlEgXSxdH;4bYNqfHliYYPzZZk> MUe5OkBp MnPIR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKN0GGUj3SSXMh[2WubIOgZZN{\XO|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgPVYhcHK|IHL5JGdq\W2|YTDzeIFqdmmwZz3iZZNm\CCuaXfoeEBucWO{b4Pjc5B6NCCLQ{WwQVAvODBzMzFOwG0> NXewNY5oOjVyMkW5PVE>
OVCAR8 cells MX3DfZRwfG:6aXPpeJkh[XO|YYm= Mnz6R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gU3ZESVJ6IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHL5JJRzgXCjbjDicJVmKGW6Y3z1d4lwdiCjc4PhfUwhUUN3ME2wMlAxOTNizszN Mn;PNlMzOTR2NUK=
HuTu 80 cells M{fuU3Bzd2yrZnXyZZRqd25iYYPzZZk> M4fzSFczKGh? MYjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDpckBpfW2jbjDIeXR2KDhyIHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODF|NzFOwG0> M4\BRVIzOzJ7NU[x
K562 cells NYDTV3l[S3m2b4TvfIlkcXS7IHHzd4F6 M33GRWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGs2PjJiY3XscJMtKEmFNUC9NE4xODF2IN88US=> M3nvU|E6QDN5NUm0
NCI/ADR (MDR) cells M1LkbmZ2dmO2aX;uJIF{e2G7 MUXD[YxtKGO7Y3zlJIFzemW|dDDpckBPS0lxQVTSJEhOTFJrIHPlcIx{KGK7IHHjZ5VufWyjdHnvckBifCCJMj;NJJBp[XOnLDDJR|UxRTBwMECxOUDPxE1? NEjIfo8yPjN5N{G4Oy=>
HUVEC NFrCeoJRem:uaX\ldoF1cW:wIHHzd4F6 M3XleGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGXWSWMtKEmFNUC9NE4xODF3IN88US=> MorBNVY4OjJ4M{O=
KB cell M4XEfHBzd2yrZnXyZZRqd25iYYPzZZk> Mn72RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNQjDj[YxtKGyrbnWgZpkhdWW2aIns[Y5mKGKudXWg[JlmKGG|c3H5MEBKSzVyPUCuNFAyPSEQvF2= NULuPWhOOTdyM{SxOFc>
KB-VIN10 cell NELaTpRRem:uaX\ldoF1cW:wIHHzd4F6 MWTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEuELW\JUlExKGOnbHygcIlv\SCkeTDt[ZRpgWynbnWgZox2\SCmeXWgZZN{[XluIFnDOVA:OC5yMEG1JO69VQ>? MkjmNVcxOzRzNEe=
Human SH-SY5Y neuroblastoma cells M{P1[mZ2dmO2aX;uJIF{e2G7 NV7He2p1UW6qaXLpeI9zgSClb37j[Y51emG2aX;uJIFo[Wmwc4SgTJVu[W5iU1itV3k2YSCwZYXyc4Jt[XO2b33hJINmdGy|LDDJR|UxRTBwMECxOUDPxE1? NHPlVWUyPTl4M{eyNi=>
SW620 cells NFLhNIhRem:uaX\ldoF1cW:wIHHzd4F6 MYe3NkBp NGrISXJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBqdiCqdX3hckBUXzZ{MDDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODBzNUKg{txO MXuyNlMzQTV4MR?=
Molt4/C8 cells NWjFTZUxWHKxbHnm[ZJifGmxbjDhd5NigQ>? M2SwWWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTX;seFQwSzhiY3XscJMtKEmFNUC9NE4xODF4IN88US=> M2nBWVE4ODN2MUWw
ACHN cell MnHDVJJwdGmoZYLheIlwdiCjc4PhfS=> M2fsNGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4Sg[JJ2\yC{ZYPpd5RidnRiQVPIUkBk\WyuIHzpcoUh\XiycnXzd4lv\yCPRGKxJIJ6KEGuYX3hdkBDdHWnIHHzd4F6NCCLQ{WwQVAvODBzNjFOwG0> MnHXNVczQDZ|OUO=
Molt4/C8 cells M4fDTXBzd2yrZnXyZZRqd25iYYPzZZk> MUGzJIRigXN? NEHpPJZCdnSrcILvcIln\XKjdHn2[UBm\m[nY4SgZYdicW6|dDDoeY1idiCPb3z0OE9EQCClZXzsd{Bi\nSncjCzJIRigXNuIFnDOVA:OC5yMEG2JO69VQ>? MmrCNVc1OTl4MEe=

... Click to View More Cell Line Experimental Data

In vivo In NT2 and MDA-MB-231 mammary tumor model, administration of Combretastatin A4 (100 mg/kg, i.p.) induces a significant decrease in lipids R1 and a reduction in tumor pO2 measured by electron paramagnetic resonance (EPR) oximetry.[2] Combretastatin A4 (100 mg/kg, i.p.) significant decreases the Ktrans in male NMRI mice.[3]

Protocol

Kinase Assay:[1]
+ Expand

Competitive binding assay using LC-MS/MS:

Colchicine (1.2 μ M) is incubated with tubulin (1.3 mg/mL) in the incubation buffer (80 mM PIPES, 2.0 mM MgCl2, 0.5 mM EGTA, pH 6.9) at 37℃ for 1 h. Varying concentrations (0.1 − 125 μ M) of Combretastatin A4 are used to compete with colchicine originally bound to tubulin. After incubation, the filtrate is obtained. The ability of the analogue to inhibit the binding of colchicine is expressed as a percentage of control binding in the absence of any competitor.
Cell Research:[1]
+ Expand
  • Cell lines: MDA-MB-231, A549, and Hela cells
  • Concentrations: ~3.8 nM
  • Incubation Time: 72 h
  • Method: MDA-MB-231, A549, and HeLa cells are grown in DMEM medium (115 units/mL of penicillin G, 115 μg/mL of streptomycin, and 10% fetal bovine serum). Cells are seeded in 96-well plates (5000 cells/well) containing 50 μL of growth medium for 24 h. After medium removal, 100 μL of fresh medium containing individual analogue compounds at different concentrations is added to each well and incubated at 37 ℃ for 72 h. After 24 h of culture, the cells are supplemented with 50 μL of analogue compounds dissolved in DMSO (less than 0.25% in each preparation). After 72 h of incubation, 20 μL of resazurin is added for 2 h before recording fluorescence at 560 nm (excitation) and 590 nm (emission) using a Victor microtiter plate fluorimeter. The IC50 is defined as the compound concentration required to inhibit cell proliferation by 50% in comparison with cells treated with the maximum amount of DMSO (0.25%) and considered as 100% viability.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: FVB/N or nude NMRI female mice bearing NT2 and MDA-MB-231 tumors
  • Formulation: DMSO
  • Dosages: 100 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 63 mg/mL (199.14 mM)
Ethanol 34 mg/mL warmed (107.47 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+50% PEG 300+ddH2O
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 316.35
Formula

C18H20O5

CAS No. 117048-59-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00395434 Completed Tumors Mateon Therapeutics September 2006 Phase 1
NCT00395434 Completed Tumors Mateon Therapeutics September 2006 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to make solution for in vivo IP injection?

  • Answer:

    We've tested some vehicles for S7783 Combretastatin A4, and found it can be dissolved in 5% DMSO+50% PEG 300+ddH2O at 30mg/ml clearly. When prepare the solution, please dissolve the compound in DMSO clearly first. The add PEG, after they mixed well, then dilute with water.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products0

Tags: buy Combretastatin A4 | Combretastatin A4 supplier | purchase Combretastatin A4 | Combretastatin A4 cost | Combretastatin A4 manufacturer | order Combretastatin A4 | Combretastatin A4 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID